

Seeking Novel RNA Therapeutics for Oncology Indications

A US-based, publicly traded biotechnology company focused in the area of oncology drug development is seeking **early-stage nucleic acid therapeutics for cancer treatment**. Specifically, our client is interested in **RNA-based therapies** that have proven efficacy of **causing tumor cell death** to take advantage of their existing tumor-targeting delivery platform.



Approaches of Interest:

- All cancers are within scope
- Open to all RNA modalities (e.g. siRNA, mRNA, antisense oligonucleotides)
- Open to all mechanisms and pathways that directly lead to the death of tumor cells
- Therapeutics with relatively low potency (e.g. EC50 within the μM range) are also relevant for this campaign

Out of Scope:

- RNA therapeutics that knockdown resistance to other cancer therapeutics

Developmental Stages of Interest:

- Opportunities from preclinical to Phase 1 are in scope
- Opportunities should have a minimum of *in vitro* validation






Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **29th July 2024 - 10:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk